Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Urological surgeon Vladimir Medvedev uses a Da Vinci robotic surgical system. Photo: Valery Matytsin/TASS/Getty Images
Researchers have long been skeptical about whether surgical robots lead to better clinical outcomes than traditional surgical techniques. And now the FDA wants to make sure more patients and surgeons are aware of the pitfalls.
What they're saying: Surgical robots have not been officially labeled as safe or effective "in mastectomy procedures or the prevention or treatment of cancer," the FDA wrote Thursday in a public safety notice.
- Translation: Patients should be studious. Doctors should fully explain the risks or robotic surgery, and shouldn't hype it up.
By the numbers: Intuitive Surgical, one of the world's largest makers of surgical robots, collected more than $1.1 billion of profit from $3.7 billion of revenue in 2018. Intuitive's stock is up 161% since the start of 2017, putting the company's market value around $63 billion.
Go deeper: Johnson & Johnson acquires surgical robot firm Auris